- Home
- ATXI
as 05-10-2024 4:00pm EST
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It focuses on developing its product candidate, AJ201, for spinal and bulbar muscular atrophy, BAER-101, for the treatment of epilepsy and panic disorders, and IV Tramadol for the management of moderate-to-moderately-severe pain in adults.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BAY HARBOR ISLANDS |
| Market Cap: | 2.8M | IPO Year: | 2017 |
| Target Price: | $56.25 | AVG Volume (30 days): | 58.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -73.50 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.00 - $93.75 | Next Earning Date: | 05-21-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of Avenue Therapeutics Inc. (ATXI)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Davidow Robert L | ATXI | 10% Owner | Dec 11 '23 | Sell | $0.14 | 264,000 | $36,960.00 | 681,000 | SEC Form 4 |
| Davidow Robert L | ATXI | 10% Owner | Dec 11 '23 | Sell | $0.15 | 18,000 | $2,700.00 | 22,000 | SEC Form 4 |
| Davidow Robert L | ATXI | 10% Owner | Dec 11 '23 | Sell | $0.14 | 61,000 | $8,540.00 | 74,000 | SEC Form 4 |
| Davidow Robert L | ATXI | 10% Owner | Dec 11 '23 | Sell | $0.14 | 126,000 | $17,640.00 | 215,800 | SEC Form 4 |
| Davidow Robert L | ATXI | 10% Owner | Dec 11 '23 | Sell | $0.14 | 128,000 | $17,920.00 | 147,000 | SEC Form 4 |
| Davidow Robert L | ATXI | 10% Owner | Dec 11 '23 | Sell | $0.14 | 20,000 | $2,800.00 | 80,000 | SEC Form 4 |
Latest Avenue Therapeutics Inc. News
ATXI Breaking Stock News: Dive into ATXI Ticker-Specific Updates for Smart Investing
GlobeNewswire
13 days ago
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
GlobeNewswire
18 days ago
Avenue Therapeutics Announces Reverse Stock Split
GlobeNewswire
2 months ago
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
GlobeNewswire
2 months ago
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
GlobeNewswire
2 months ago
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
GlobeNewswire
2 months ago
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
GlobeNewswire
3 months ago
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
GlobeNewswire
3 months ago